GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies
- Conditions
- Obstetric Labour, Premature
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 98
- Registration Number
- NCT02292784
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm Labour
- Conditions
- Obstetric Labour, Premature
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 97
- Registration Number
- NCT02292771
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02292732
A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT02289495
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT02289482
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study
- Conditions
- Meningococcal DiseaseInfections, Meningococcal
- Interventions
- Biological: Meningococcal quadrivalent CRM-197 conjugate vaccine
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 144
- Registration Number
- NCT02287688
- Locations
- 🇺🇸
GSK Investigational Site, Pasadena, California, United States
Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
- Conditions
- Meningococcal Disease
- Interventions
- Biological: PlaceboBiological: Meningococcal ABCWY
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 189
- Registration Number
- NCT02285777
- Locations
- 🇺🇸
GSK Investigational Site, Cleveland, Ohio, United States
Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Biological: Placebo weekly injectionBiological: Albiglutide weekly injectionBiological: Insulin
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 67
- Registration Number
- NCT02284009
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
- Conditions
- Asthma
- Interventions
- Biological: MepolizumabDrug: PlaceboDrug: SOC
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 556
- Registration Number
- NCT02281318
- Locations
- 🇬🇧
GSK Investigational Site, Swansea, United Kingdom
Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects
- Conditions
- Purpura, Thrombocytopenic, Idiopathic
- Interventions
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 39
- Registration Number
- NCT02281370
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States